Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Enterovirus 71（EV71） Inactivated Vaccine in Children Aged 36-71 Months

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers ≥ 2 years old;~* Proven legal identity;~* Participants or guardians of the participants should be capable of understanding the written consent form, and such form should be signed prior to enrolment.~Exclusion Criteria:~* Prior vaccination with EV71 vaccine;~* History of hand, foot and mouth disease;~* History of allergy to any vaccine or vaccine ingredient, asthma, serious adverse reactions to vaccination, such as urticaria, dyspnea, angioneurotic edema, abdominal pain, etc;~* Congenital malformation, developmental disorders, genetic defects, or severe malnutrition;~* Autoimmune disease or immunodeficiency/immunosuppressive;~* Severe/uncontrollable nervous system disease (epilepsy, seizures or convulsions) or mental illness;~* History of thyroidectomy, no spleen and functional spleen;~* Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders;~* Receipt of any of the following products:~  1. Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) within 6 month prior to study entry~ 2. Blood products within 2 months prior to study entry~ 3. Any other investigational products (drug or vaccine）within 30 days prior to study entry~ 4. Any live attenuated vaccine within 14 days prior to study entry~ 5. Any subunit vaccine or inactivated vaccine within 7 days prior to study entry;~* Acute disease or acute stage of chronic disease within 7 days prior to study entry;~* Axillary temperature \> 37.0 °C;~* Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 71 Months
- Healthy Volunteers: t

Study Arms:
- Experimental group (Type: EXPERIMENTAL): 36-71 months old children-experimental EV71 vaccine.
- Vaccine-controlled group (Type: ACTIVE_COMPARATOR): 36-71 months old children-control EV71 vaccine.
- Age-controlled group (Type: ACTIVE_COMPARATOR): 6-35 months old children-experimental EV71 vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).